Morgan Stanley’s Sonoma Pharmaceuticals SNOA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.46K | Sell |
2,000
-4
| -0.2% | -$6 | ﹤0.01% | 7364 |
|
|
2026
Q1 | $4.27K | Buy |
2,004
+2,000
| +50,000% | +$5.85K | ﹤0.01% | 7178 |
|
|
2025
Q4 | $15 | Hold |
4
| – | – | ﹤0.01% | 8112 |
|
|
2025
Q3 | $16 | Hold |
4
| – | – | ﹤0.01% | 8075 |
|
|
2025
Q2 | $11 | Hold |
4
| – | – | ﹤0.01% | 8026 |
|
|
2025
Q1 | $9 | Hold |
4
| – | – | ﹤0.01% | 8015 |
|
|
2024
Q4 | $11 | Hold |
4
| – | – | ﹤0.01% | 7908 |
|
|
2024
Q3 | $12 | Hold |
4
| – | – | ﹤0.01% | 7857 |
|
|
2024
Q2 | $18 | Hold |
4
| – | – | ﹤0.01% | 7746 |
|
|
2024
Q1 | $14 | Sell |
4
-5
| -56% | -$16 | ﹤0.01% | 7748 |
|
|
2023
Q4 | $32 | Buy |
9
+5
| +125% | +$32 | ﹤0.01% | 7729 |
|
|
2023
Q3 | $66 | Hold |
4
| – | – | ﹤0.01% | 7473 |
|
|
2023
Q2 | $92 | Hold |
4
| – | – | ﹤0.01% | 7504 |
|
|
2023
Q1 | $84 | Hold |
4
| – | – | ﹤0.01% | 7583 |
|
|
2022
Q4 | $96 | Hold |
4
| – | – | ﹤0.01% | 7702 |
|
|
2022
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 7856 |
|
|
2022
Q2 | $0 | Sell |
4
-1
| -20% | -$64 | ﹤0.01% | 7953 |
|
|
2022
Q1 | $0 | Sell |
5
-122
| -96% | -$8.82K | ﹤0.01% | 8102 |
|
|
2021
Q4 | $11K | Buy |
127
+122
| +2,440% | +$13K | ﹤0.01% | 7447 |
|
|
2021
Q3 | $0 | Sell |
5
-4
| -44% | -$493 | ﹤0.01% | 8015 |
|
|
2021
Q2 | $1K | Hold |
9
| – | – | ﹤0.01% | 7629 |
|
|
2021
Q1 | $1K | Hold |
9
| – | – | ﹤0.01% | 7379 |
|
|
2020
Q4 | $1K | Sell |
9
-130
| -94% | -$19.8K | ﹤0.01% | 6968 |
|
|
2020
Q3 | $23K | Buy |
139
+126
| +969% | +$19.4K | ﹤0.01% | 6012 |
|
|
2020
Q2 | $2K | Hold |
13
| – | – | ﹤0.01% | 6463 |
|
|
2020
Q1 | $1K | Hold |
13
| – | – | ﹤0.01% | 6485 |
|
|
2019
Q4 | $1K | Hold |
13
| – | – | ﹤0.01% | 6586 |
|
|
2019
Q3 | $1K | Hold |
13
| – | – | ﹤0.01% | 6571 |
|
|
2019
Q2 | $2K | Hold |
13
| – | – | ﹤0.01% | 6473 |
|
|
2019
Q1 | $2K | Hold |
13
| – | – | ﹤0.01% | 6467 |
|
|
2018
Q4 | $2K | Sell |
13
-5
| -28% | -$997 | ﹤0.01% | 6435 |
|
|
2018
Q3 | $5K | Hold |
18
| – | – | ﹤0.01% | 6451 |
|
|
2018
Q2 | $8K | Hold |
18
| – | – | ﹤0.01% | 6355 |
|
|
2018
Q1 | $12K | Hold |
18
| – | – | ﹤0.01% | 6232 |
|
|
2017
Q4 | $18K | Hold |
18
| – | – | ﹤0.01% | 6106 |
|
|
2017
Q3 | $17K | Buy |
18
+3
| +20% | +$3.25K | ﹤0.01% | 6058 |
|
|
2017
Q2 | $17K | Buy |
15
+4
| +36% | +$4.93K | ﹤0.01% | 6123 |
|
|
2017
Q1 | $14K | Buy |
11
+3
| +38% | +$3.49K | ﹤0.01% | 6170 |
|
|
2016
Q4 | $7K | Hold |
8
| – | – | ﹤0.01% | 6232 |
|
|
2016
Q3 | $6K | Buy |
8
+6
| +300% | +$4.51K | ﹤0.01% | 6207 |
|
|
2016
Q2 | $2K | Sell |
2
-1
| -33% | -$861 | ﹤0.01% | 6371 |
|
|
2016
Q1 | $3K | Hold |
3
| – | – | ﹤0.01% | 6363 |
|
|
2015
Q4 | $3K | Sell |
3
-12
| -80% | -$12.8K | ﹤0.01% | 6464 |
|
|
2015
Q3 | $17K | Sell |
15
-28
| -65% | -$33.2K | ﹤0.01% | 6099 |
|
|
2015
Q2 | $55K | Buy |
43
+39
| +975% | +$36.5K | ﹤0.01% | 5825 |
|
|
2015
Q1 | $3K | Sell |
4
-2
| -33% | -$1.7K | ﹤0.01% | 6401 |
|
|
2014
Q4 | $9K | Buy |
6
+2
| +50% | +$3.12K | ﹤0.01% | 6235 |
|
|
2014
Q3 | $8K | Sell |
4
-3
| -43% | -$6.98K | ﹤0.01% | 6245 |
|
|
2014
Q2 | $20K | Sell |
7
-163
| -96% | -$482K | ﹤0.01% | 6030 |
|
|
2014
Q1 | $578K | Buy |
170
+72
| +73% | +$245K | ﹤0.01% | 4450 |
|
|
2013
Q4 | $307K | Sell |
98
-33
| -25% | -$87.7K | ﹤0.01% | 4801 |
|
|
2013
Q3 | $322K | Sell |
131
-13
| -9% | -$31.7K | ﹤0.01% | 4616 |
|
|
2013
Q2 | $334K | Buy |
+144
| New | +$515K | ﹤0.01% | 4535 |
|
Other funds holding SNOA
VCM
MCWS
GRP
VFT
HI
QWM
Morgan Stanley's SNOA Position: Q2 2026 in Review
Morgan Stanley reduced its Sonoma Pharmaceuticals (SNOA) stake by 0.2% in Q2 2026, selling an estimated $6 and leaving 2,000 shares worth $2.46K. The position accounts for ﹤0.01% of the portfolio, ranked #7364.
Morgan Stanley first reported a position in SNOA in Q2 2013 and has held it in 53 quarters since. The position peaked at $578K in Q1 2014. 12 funds tracked by Wall St. Rank hold SNOA as of Q2 2026.
- Morgan Stanley held 2,000 shares of Sonoma Pharmaceuticals worth $2.46K as of Q2 2026.
- Morgan Stanley sold 4 Sonoma Pharmaceuticals shares in Q2 2026, an estimated $6.
- Sonoma Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7364 holding.
- Morgan Stanley first reported a position in Sonoma Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Morgan Stanley's Sonoma Pharmaceuticals position peaked at $578K in Q1 2014.
- 12 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.